Previous 10 | Next 10 |
Danaher ( NYSE: DHR ) is scheduled to announce Q4 earnings results on Tuesday, January 24th, before market open. The consensus EPS Estimate is $2.51 (-6.7% Y/Y) and the consensus Revenue Estimate is $7.9B (-2.9% Y/Y). Over the last 2 years, DHR has beaten EPS estimates 100...
Summary The Top Six Healthcare Products and Service companies are some of the most popular investments in the market. However, they offer varying financial profiles. To understand where opportunity may lie, I ranked the group according to various financial metrics. Read on to se...
Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For further details see: Dividend C...
Summary ETY enjoyed trading at some premiums in recent years, but the distribution cut brought it back down to flirt with a discount. This fund is more attractively valued at a discount as, historically, it has exhibited trading more at a discount than a premium. Waiting for an even...
Summary The health care sector - as measured by the Fidelity Health Care ETF - outperformed the S&P 500 by ~12.2% over the past year. That's because health care is considered to be a relatively defensive sector due to the fact that healthcare - in general - cannot be delayed, no mat...
Summary As requested by many, I decided to dedicate an article to my personal dividend growth portfolio, consisting of more than 90% of my net worth. I start by explaining my strategy and approach, followed by a discussion of the benefits that come with dividend (growth) investment stra...
Summary In this article, I revisit the life sciences "picks and shovels" market leaders Danaher Corporation and Thermo Fisher Scientific Inc. I will review changes since the initial comparative piece two quarters ago. Furthermore, I'll review their executive compensation structures....
Danaher Corporation (DHR) 41st Annual J.P. Morgan Healthcare Conference Call January 10, 2023 16:30 ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Presentation Rache...
Danaher ( NYSE: DHR ) projects its Q4 2022 non-GAAP core revenue growth will be in the high-single digits , an improvement of previously guidance of flat to a low-single digit percent decline. The life sciences company expects non-GAAP base business core revenue growth is expected...
Summary Twist operates in a trendy space, with good growth, but atrocious margins. As profits are not in the company’s DNA, losses are likely to continue. Although the stock is down a lot, it still trades at a healthy valuation. The stock has limited downside protection i...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...